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BY-NC-ND license (http://creativecomBackground/Purpose: To analyze the prognostic factors for ocular hypertension after posterior
subtenon injection of triamcinolone acetonide (PSTA) for the treatment of diabetic macular
edema (DME).
Methods: Patients who received PSTA for DME from January 2006 to December 2011 were
enrolled retrospectively and were followed until December 2012 in one hospital. Modified
Cox regression models were used to analyze the factors associated with ocular hypertension,
which was defined as an intraocular pressure> 21 mmHg after PSTA.
Results: A total of 180 PSTA injections were given to 114 eyes from 73 adults with DME. During
a mean follow-up of 50.4 weeks after each injection, ocular hypertension occurred in 20.6% of
injections (28.1% of eyes). Treatment-naı¨ve patients with proliferative diabetic retinopathy
(PDR) had a higher risk of ocular hypertension after PSTA than those with nonproliferative dia-
betic retinopathy (NPDR) [hazard ratio (HR)Z 3.255, pZ 0.030]. Intravitreal injection of bev-
acizumab (IVB) before PSTA had a significant effect in lowering the risk of ocular hypertension
after PSTA in patients with PDR who had received panretinal photocoagulation (PRP)
(HRZ 0.107, pZ 0.035). Both prompt PRP and IVB following PSTA had a protective effect
against ocular hypertension in treatment-naı¨ve patients with PDR (HRZ 0.086, pZ 0.0002
and HRZ 0.155, pZ 0.049, respectively).ave no conflicts of interest relevant to this article.
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(2016), http://dx.doi.org/10.1016/j.Conclusion: Treatment-naı¨ve patients with PDR had a higher risk of ocular hypertension after
PSTA than those with NPDR. Bevacizumab and prompt PRP both had a protective effect against
ocular hypertension after PSTA in patients with PDR.
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Diabetic retinopathy (DR) is one of the leading causes of
visual loss worldwide,1 and diabetic macular edema (DME)
is the most common cause of visual loss in patients with
DR.2 The breakdown of the blooderetinal barrier, increased
permeability of macular retinal vessels, and exudation of
serous fluid and lipids into the macula lead to visual dete-
rioration in patients with DME.3 Treatments for DME include
laser photocoagulation, corticosteroids, anti-vascular
endothelial growth factor (VEGF) administration, and pars
plana vitrectomy.2,3 Triamcinolone acetonide is a minimally
soluble repository steroid that can slowly release its con-
tents. Posterior subtenon injections of triamcinolone ace-
tonide (PSTA) and intravitreal injections of triamcinolone
acetonide (IVTA) both have been shown to decrease mac-
ular thickness and improve vision in patients with DME.4e8
Combined treatment with triamcinolone acetonide and
anti-VEGF has also been advocated to treat DME.9e11 In
addition, for patients with proliferative diabetic retinop-
athy (PDR) and concomitant DME, PSTA has been proved to
be effective in preventing panretinal photocoagulation
(PRP)-induced macular edema.12
One of the most important side effects of PSTA is ocular
hypertension after injections; some patients even require
surgical intervention to control their intraocular pressure
(IOP).13e22 Persistent ocular hypertension may also rarely
occur after intravitreal administration of anti-VEGF.23 To
the best of our knowledge, the role of anti-VEGF in ocular
hypertension after PSTA for DME has not been investigated.
In this study, we retrospectively collected data from pa-
tients who received PSTA for DME in order to investigate the
risk and protective factors regarding ocular hypertension
after PSTA; in particular, we examined the effect of anti-
VEGF as well as the severity of DR on IOP after PSTA. We
also evaluated the timing of PRP with respect to ocular
hypertension after PSTA in patients with PDR and DME.Materials and Methods
Study sample
We retrospectively collected data from patients who
received PSTA for DME in Taipei Tzu Chi Hospital, Buddhist
Tzu Chi Medical Foundation, between January 2006 and
December 2011. The follow-up period ended in December
2012. The exclusion criteria for this study were as follows:
(1) a history of glaucoma or an IOP> 21 mmHg at the time
of PSTA; (2) concurrent antiglaucoma medication at the
time of PSTA; (3) iris or angle rubeosis; (4) simultaneoussieh Y-T, et al., Bevacizumab and
triamcinolone acetonide for diab
jfma.2016.09.014systemic or intravitreal steroid treatment during the
follow-up period; (5) systemic connective tissue disease;
(6) scleral buckle or intravitreal silicone oil; (7) retinal
vascular occlusive diseases; and (8) follow-up time< 2
months. After exclusion, a total of 114 eyes from 73 pa-
tients were included in this study. The mean age at the time
of the first PSTA was 63.4 10.1 years (range, 42e89
years), and 44.7% patients were females. This research
adhered to the tenets of the Declaration of Helsinki, and
Institutional Review Board (IRB) approval was obtained
from the IRB of Taipei Tzu Chi Hospital, Buddhist Tzu Chi
Medical Foundation. Waiver of informed consent was
approved by the IRB due to the retrospective nature of this
study. Power analysis was performed to justify the number
of patients enrolled in the study.
Procedure for PSTA
The procedure for PSTA was modified according to the
method described by Nozik.24 The patient was asked to
direct his or her gaze superonasally, and an injection of
40 mg/mL of triamcinolone acetonide was administered
inferotemporally into the posterior subtenon space with a
27-gauge needle.
IOP and clinical characteristics
The IOP was measured with a noncontact tonometer (CT-
80; Topcon Corporation, Tokyo, Japan). Baseline IOP was
measured in each eye just before PSTA. Thereafter, the
IOPs were monitored at least monthly for the first 3 months.
Patients’ age, sex, and severity of DR at baseline were
recorded. The severity of DR at baseline was classified into
nonproliferative diabetic retinopathy (NPDR) or PDR, ac-
cording to the criteria proposed by the Global Diabetic
Retinopathy Project Group25; for eyes with PDR, they were
further classified according to the presence of PRP. In this
study, all the eyes with PDR without previous PRP were
treatment-naı¨ve at baseline, which means that no retinal
laser or anti-VEGF agents had been given to these patients
before PSTA. The use of anti-VEGF therapy was also
recorded. In this study, bevacizumab was the only anti-
VEGF agent used for all patients.
Outcomes and follow-up events
In this study, we defined ocular hypertension as an
IOP> 21 mmHg. The primary endpoint was defined as the
first IOP> 21 mmHg after PSTA for a single eye. More than
one PSTA treatment was performed in some eyes during thePanretinal photocoagulation protect against ocular hypertension
etic macular edema, Journal of the Formosan Medical Association
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formation obtained from the course of one PSTA treatment
in one eye was considered to be a single record. Other
possible endpoints included a subsequent PSTA treatment,
any intraocular surgery other than cataract surgery or
intravitreal injection of anti-VEGF, loss to follow-up, or end
of study.
Statistical analysis
For eyes that received multiple PSTA treatments, each
PSTA was treated as a single record. Multiple PSTA in one
eye led to multiple gap times (time period between suc-
cessive PSTAs) within the same eye, and these gap times
were correlated. The ordered nature of serial PSTA in-
jections in one eye allowed us to apply conditional
regression analysis for repeated gap times.26,27 Therefore,
stratified Cox proportional hazards (PH) models were used
to analyze the factors for ocular hypertension after PSTA,
and a robust sandwich varianceecovariance estimation
method was adopted to correct the correlation between
fellow eyes from the same patient. Paired t tests were used
to compare baseline and posttreatment IOPs. A p val-
ue< 0.05 was considered statistically significant. SAS 9.4
(SAS Institute Inc., Cary, NC, USA) software was used for all
statistical analyses.Results
A total of 180 PSTA injections were administered to the
114 eyes: 31 eyes had NPDR, 53 eyes had PDR with PRP,
and 30 eyes had PDR with no previous PRP or anti-VEGF at
baseline. The mean number of PSTA injections was 1.6
(range, 1e8) for each eye. During the study period, 29
eyes received multiple PSTA during the study period. The
minimal gap time or interval between two successive in-
jections in the same eye was 8 weeks. For each injection,
the mean follow-up time was 50.4 51.6 weeks (range,
8e280 weeks), and the mean baseline IOP was
14.0 3.2 mmHg (range, 6e21 mmHg). Among the 114
eyes, 12 eyes had received intravitreal injections ofTable 1 Baseline data for 114 eyes in this study.
Age (years), mean (SD) 63.2 (10.4)
Sex (female), n (%) 51 (44.7)
Hypertension, n (%) 57 (50.0)
Intraocular pressure (mmHg), mean (SD) 14.0 (3.3)
Severity of diabetic retinopathy, n (%)
NPDR 22 (19.3)
PDR with PRP 62 (54.4)
Treatment-naı¨ve PDR 30 (26.3)
Intravitreal bevacizumab, n (%)
Before PSTA 12 (10.5)
After PSTA 22 (19.3)
NPDRZ nonproliferative retinopathy, PDRZ proliferative reti-
nopathy, PRPZ panretinal photocoagulation, PSTAZ posterior
subtenon injection of triamcinolone acetonide.
Please cite this article in press as: Hsieh Y-T, et al., Bevacizumab and
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(2016), http://dx.doi.org/10.1016/j.jfma.2016.09.014bevacizumab (IVB) at the time of the first PSTA. During
the follow-up period, 22 additional eyes received initial
IVB injections. Additional baseline data are shown in
Table 1.
Figure 1 shows the IOP changes after PSTA. The mean
IOP increased to 15.1 3.6 mmHg at the 1st month, formed
a plateau from the 2nd to the 5th month (range,
16.0e16.2 mmHg), and then decreased gradually after the
6th month (15.5 4.8 mmHg). The IOP values measured 1e6
months after PSTA were all significantly higher than the
baseline value (p< 0.001 for the 1st to the 5th month and
pZ 0.002 for the 6th month). Ocular hypertension occurred
in 20.6% of injections (28.1% of eyes) after PSTA. The mean
event time for ocular hypertension after each injection was
16.1 14.7 weeks (range, 2e77 weeks, medianZ 11
weeks). Among the 114 eyes in this study, 21 eyes (18.4%)
received antiglaucoma agents during the study period, 3
eyes (2.6%) received surgical removal of subtenon triam-
cinolone acetonide particles, and 2 eyes (1.8%) received
filtering surgery for IOP control.Factors associated with ocular hypertension after
PSTA
Baseline characteristics
Table 2 shows the unadjusted and adjusted hazard ratios
(HRs) of baseline characteristics for ocular hypertension
after PSTA determined by stratified Cox PH models. Eyes
with a baseline IOP> 15 mmHg had a higher risk of ocular
hypertension after PSTA than did those with a baseline
IOP 15 mmHg (adjusted HRZ 4.003, p< 0.001). For
treatment-naı¨ve eyes with PDR, the risk of ocular hyper-
tension after PSTA was 3.255 times that for eyes with NPDR
after adjustment for the remaining risk factors (pZ 0.030).
IVB before and after PSTA
The effects of IVB in patients with different degrees of
severity of DR are shown in Table 3. In the NPDR group,
neither IVB before nor after PSTA had a significant effect on
ocular hypertension following PSTA (p> 0.05 for both
comparisons). For eyes with PDR and complete PRP, IVB
before PSTA provided a protective effect against ocular
hypertension after PSTA (HRZ 0.107, pZ 0.035); however,
IVB after PSTA was not protective (HRZ 0.919, pZ 0.88).
For treatment-naı¨ve eyes with PDR, IVB after PSTA also
provided a protective effect against ocular hypertension
following PSTA (HRZ 0.155, pZ 0.049).
Prompt vs. deferred PRP
For treatment-naı¨ve eyes with PDR, prompt PRP following
PSTA was shown to have a protective effect against ocular
hypertension after PSTA compared with deferred PRP
(HRZ 0.086, pZ 0.0002) after adjustments for age, sex,
and baseline IOP (Table 3).
Combined effect of prompt PRP and IVB after PSTA
For treatment-naı¨ve eyes with PDR, prompt PRP plus IVB
after PSTA provided a protective effect against ocular hy-
pertension after PSTA compared with deferred PRP only
(HRZ 0.050, pZ 0.0007) after adjustments for age, sex,
and baseline IOP (Table 3).Panretinal photocoagulation protect against ocular hypertension
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Figure 1 Intraocular pressure at baseline and after posterior subtenon injection of triamcinolone acetonide.
Table 2 Factors associated with ocular hypertension after posterior subtenon injection of triamcinolone acetonide by
stratified Cox regression analysis.
Simple regression Multiple regression
Hazard ratio 95% CI p Hazard ratio 95% CI p
Age 0.988 0.955e1.023 0.50 0.984 0.940e1.031 0.50
Sex
Female 1 (reference) 1 (reference)
Male 1.601 0.792e3.238 0.19 1.947 0.952e3.982 0.068
Baseline IOP
 15 mmHg 1 (reference) 1 (reference)
> 15 mmHg 3.096 1.645e5.828 < 0.001 4.003 1.975e8.112 < 0.001
Severity of diabetic retinopathy
NPDR 1 (reference) 1 (reference)
PDR with PRP 1.862 0.790e4.389 0.16 1.970 0.786e4.938 0.15
Treatment-naı¨ve PDR 2.468 0.860e7.087 0.093 3.255 1.124e9.426 0.030
IOPZ intraocular pressure, NPDRZ nonproliferative retinopathy, PDRZ proliferative retinopathy, PRPZ panretinal photocoagulation.
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In this study, 29 eyes received multiple PSTA, and the
number of previous PSTA was evaluated as an explanatory
variable in the Cox regression model with adjustment for
age, sex, and other clinical variables. The results showed
that the number of previous injections was not associated
with the risk of ocular hypertension (HRZ 1.171,
pZ 0.78).Discussion
Glucocorticoids have been proved to be effective in treat-
ing DR and DME by means of their antiinflammatory action
and direct inhibition of VEGF expression. They also have
neuroprotective properties, in contrast to the possible
neurotoxic effects of VEGF inhibitors.28 Although anti-VEGFPlease cite this article in press as: Hsieh Y-T, et al., Bevacizumab and
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(2016), http://dx.doi.org/10.1016/j.jfma.2016.09.014therapy has become the mainstream treatment of DME,
triamcinolone acetonide is still indispensable due to its cost
effectiveness.29 IVTA or PSTA in combination with an anti-
VEGF agent has also been shown to be equally or even
more effective than anti-VEGF agents alone in treating
DME.9e11 A common side effect of intraocular steroid use is
ocular hypertension, which may result in glaucomatous
optic nerve atrophy if uncontrolled. Therefore, it is
important to monitor IOP and to consider the risk factors for
ocular hypertension after PSTA. Because patients with DME
may receive repeated PSTA treatments, it is even more
clinically necessary to monitor IOP and to investigate the
factors associated with the risk of developing ocular hy-
pertension following each PSTA injection. Therefore, in this
study, we calculated the time interval from each PSTA to
the occurrence of ocular hypertension and defined the
latter as the major event time per injection in one eye.Panretinal photocoagulation protect against ocular hypertension
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Table 3 Effects of bevacizumab and panretinal photocoagulation on ocular hypertension after posterior subtenon injection of
triamcinolone acetonide in patients with different degrees of severity of diabetic retinopathy by stratified Cox regression
analysis.
Simple regression Multiple regression
Hazard ratio 95% CI p Hazard ratio 95% CI p
NPDR group:
IVB effect:
No IVB 1 (reference) 1 (reference)
IVB before PSTA 2.951 0.129e67.273 0.50 3.531 0.148e84.250 0.44
IVB after PSTA 3.727 0.657e21.157 0.14 4.346 0.743e25.427 0.10
PDR with PRP group:
IVB effect:
No IVB 1 (reference) 1 (reference)
IVB before PSTA 0.118 0.016e0.876 0.037 0.107 0.013e0.855 0.035
IVB after PSTA 0.834 0.234e2.973 0.78 0.919 0.304e2.775 0.88
Treatment-naı¨ve PDR group:
IVB effect:
Prompt PRP 1 (reference) 1 (reference)
Prompt PRP plus IVB after PSTA 0.474 0.065e3.443 0.46 0.155 0.024e0.999 0.049
Prompt vs. deferred PRP:
Deferred PRP 1 (reference) 1 (reference)
Prompt PRP 0.159 0.053e0.477 0.001 0.086 0.023e0.313 0.0002
Combined effect of prompt PRP plus IVB:
Deferred PRP 1 (reference) 1 (reference)
Prompt PRP plus IVB after PSTA 0.163 0.019e1.433 0.10 0.050 0.009e0.282 0.0007
IVBZ intravitreal injection of bevacizumab, NPDRZ nonproliferative retinopathy, PDRZ proliferative retinopathy, PRPZ panretinal
photocoagulation.
*All the multiple regression models were performed after adjustment for age, sex, and pretreatment IOP.
Ocular hypertension after subtenon triamcinolone 5
+ MODELPrevious studies demonstrated that the proportion of
patients who developed secondary glaucoma or ocular
hypertension after PSTA ranged from 11.4% to 46%.13e22
The criteria for glaucoma or ocular hypertension, how-
ever, varied among these studies. An IOP normally ranges
from 10 to 21 mmHg, and an absolute IOP> 21 mmHg is
usually considered suspicious for glaucoma. In this study,
we defined an IOP> 21 mmHg as the criterion for ocular
hypertension; the results showed that ocular hypertension
occurred in 20.6% of injections and 28.1% of eyes after
PSTA during the follow-up period. The mean follow-up
time for each injection in this study was 50.4 weeks,
which was longer than the follow-up time in most previous
studies. The mean and median event times for ocular
hypertension were 16.1 and 11 weeks, respectively, which
indicates that careful IOP monitoring during the first 3e4
months after PSTA was mandatory. However, it is worth
noting that two patients in this study first experienced
ocular hypertension at 77 and 46 weeks after PSTA
although it cannot be confirmed if the ocular hypertension
was caused by PSTA in these two cases.
In this study, treatment-naı¨ve eyes with PDR were found
to have a significantly higher risk of ocular hypertension
after PSTA than did those with NPDR. According to the study
design, cases with a history of glaucoma, including neo-
vascular glaucoma, and cases with iris rubeosis were
excluded at enrollment. However, some of the PDR patients
may develop subclinical angle rubeosis with partially
occluded anterior chamber angles during the follow-up
periods. Such patients may have presented with normalPlease cite this article in press as: Hsieh Y-T, et al., Bevacizumab and
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(2016), http://dx.doi.org/10.1016/j.jfma.2016.09.014baseline IOPs, but may have been prone to ocular hyper-
tension after PSTA. As to eyes with PDR and prior PRP, the
risk for ocular hypertension after PSTA was not significantly
different from that of patients with NPDR. These results are
reasonable because angiogenetic activity should have
decreased after PRP, and the possibility of angle rubeosis
may also have decreased.
For eyes with PDR and PRP, IVB before PSTA significantly
reduced the risk of ocular hypertension after PSTA. For
treatment-naı¨ve patients with PDR, IVB after PSTA also
significantly reduced the risk of ocular hypertension after
PSTA. As mentioned above, some patients with PDR, even
with complete PRP, might develop subclinical angle rubeosis
with partially occluded anterior chamber angles and, thus,
were prone to ocular hypertension after PSTA. Furthermore,
the ocular hypertension after PSTA in some PDR patients
possibly was due to the later onset of neovascular glaucoma
rather than steroid-induced ocular hypertension. Anti-VEGF
agents have shown promising effects for the treatment of
patients with neovascular glaucoma.30 Therefore, IVB in
these cases may suppress the angle rubeosis in the injected
eyes, thus allowing better aqueous outflow to protect
against the steroid-induced ocular hypertension or control
the neovascular glaucoma itself. According to such results,
we suggest anti-VEGF therapy should be considered in
combination with PSTA for the treatment of DME in patients
with PDR in order to decrease the incidence of ocular hy-
pertension after PSTA. Further investigations should enroll
patients prospectively to confirm the role of anti-VEGF in
steroid-induced ocular hypertension.Panretinal photocoagulation protect against ocular hypertension
etic macular edema, Journal of the Formosan Medical Association
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decades. However, PRP may result in macular edema and
visual deterioration in PDR patients who previously had
good vision.31 Proinflammatory cytokines, such as
interleukin-6 and regulated on activation normal T cell
expressed and secreted (RANTES), but not VEGF, were
found to be related to PRP-induced macular edema.32 PSTA
has been shown to effectively suppress leukocyte dynamics
and to prevent PRP-induced macular edema and visual
impairment.12,33 However, for patients with persistent se-
vere DME, the timing of PRP is still controversial. In this
study, we found that prompt PRP following PSTA had a
protective effect against ocular hypertension after PSTA
compared with deferred PRP for treatment-naı¨ve eyes with
concomitant PDR and DME. Besides, we also found that
prompt PRP plus IVB had additive effects in protecting
against ocular hypertension after PSTA. This result is
compatible with our suggestion above that ocular hyper-
tension may be related to the extent of angiogenetic ac-
tivity. Regarding concerns about the progression of PRP-
induced macular edema, both triamcinolone acetonide
and anti-VEGF agents have been proved to be effective in
suppressing PRP-related macular edema and promoting
short-term visual improvement after PRP.34 Accordingly,
PRP should be performed promptly following PSTA or
intravitreal anti-VEGF in treatment-naı¨ve patients with PDR
with concomitant DME; deferred PRP after resolution of
macular edema is not necessary and may be harmful due to
persistent secretion of VEGF from the ischemic retina and
increased risk of ocular hypertension.
Inatani et al19 and Hirano et al21 found that a higher
baseline IOP was associated with a higher incidence of
ocular hypertension. The present study also showed that
for eyes with a baseline IOP> 15 mmHg, the risk of ocular
hypertension was 4.003 times the risk of eyes with a
baseline IOP 15 mmHg. These results suggest that in pa-
tients with high baseline IOPs who undergo PSTA, post-
operative IOPs should be carefully monitored.
To evaluate the cumulative effect of serial PSTA on
ocular hypertension, we used stratified Cox PH models to
allow that eyes with different numbers of injections had
different risks of ocular hypertension for the same eye; if
the number of injections has a significant correlation with
ocular hypertension after PSTA, it might suggest the un-
derlying cumulative effects of serial PSTA. In the present
study, it is found that the number of previous injections was
not associated with ocular hypertension after adjustment
for the baseline IOP for each injection and other factors. On
the other hand, Iwao et al18 reported that the difference
between peak and baseline IOPs significantly increased as
the number of injections increased; however, we think it
would be arbitrary to conclude a cumulative effect of serial
PSTA on IOP elevation because the IOP at enrollment,
instead of the pretreatment IOP before each injection, was
used as the baseline IOP for analysis in the study by Iwao
et al. Regarding the possible side effects of ocular hyper-
tension following PSTA, we propose that ophthalmologists
should consider the patient’s pretreatment IOP before each
injection, instead of the number of injections she or he has
previously received.
Several previous studies showed that younger age was
associated with a higher risk of post-PTSA ocularPlease cite this article in press as: Hsieh Y-T, et al., Bevacizumab and
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(2016), http://dx.doi.org/10.1016/j.jfma.2016.09.014hypertension.17e22 Yamamoto et al20 found that the inci-
dence of ocular hypertension was relatively higher in fe-
males; however, other studies found that the patient’s sex
was not related to ocular hypertension.18,22 The age and
sex distributions of the participants in the present study
were similar to those in previous studies. We found that
neither age nor sex was related to ocular hypertension
following PSTA.
The major limitation of this study is its retrospective
design. There were no consistent treatment protocols for
the study cases. The selection and timing for PSTA or IVB
were based on not only the severity of DME but also on the
patients’ economic burdens and personal choices. Howev-
er, we excluded cases with pre-existing glaucoma and angle
rubeosis. Therefore, patients’ subjective selection for IVB
was more of a noninformative bias, and the significant re-
sults regarding the protective effect of IVB against ocular
hypertension following PSTA in PDR patients should be
robust. On the other hand, the tonometer used in this study
was a noncontact one instead of a standard Goldmann
applanation apparatus. However, the accuracy and reli-
ability of the tonometer used in this study (Topcon CT-80)
have been documented.35 Therefore, bias from the
tonometer should be limited and noninformative.
In conclusion, we found that IOP significantly increased
from 1 to 6 months after PSTA for DME and that post-
operative ocular hypertension can occur as soon as 2 weeks
or as late as more than 1 year after PSTA. After a mean
follow-up of 50.4 weeks for each injection, ocular hyper-
tension occurred in 20.6% of injections and 28.1% of eyes.
Treatment-naı¨ve patients with PDR had a higher risk of
ocular hypertension after PSTA than those with NPDR. For
patients of PDR with previous PRP, IVB before PSTA had a
protective effect against ocular hypertension following
PSTA. Compared with deferred PRP, prompt PRP and IVB
both had a protective effect against ocular hypertension
following PSTA for treatment-naı¨ve patients with PDR.References
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